Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

Aims The primary aims of these two single‐centre, randomized, evaluator‐blind, placebo/positive‐controlled, parallel‐group studies were to evaluate the potential for pharmacodynamic and pharmacokinetic interaction between ezetimibe 0.25, 1, or 10 mg and simvastatin 10 mg (Study 1), and a pharmacody...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2002-09, Vol.54 (3), p.309-319
Hauptverfasser:	Kosoglou, Teddy, Meyer, Ingo, Veltri, Enrico P., Statkevich, Paul, Yang, Bo, Zhu, Yali, Mellars, Lillian, Maxwell, Stephen E., Patrick, James E., Cutler, David L., Batra, Vijay K., Affrime, Melton B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Anticholesteremic Agents - administration & dosage Anticholesteremic Agents - pharmacokinetics Anticholesteremic Agents - pharmacology Azetidines - administration & dosage Azetidines - pharmacokinetics Azetidines - pharmacology Biological Availability Body Mass Index cholesterol absorption inhibitor Cholesterol, LDL - antagonists & inhibitors Dose-Response Relationship, Drug Drug Combinations drug interaction Drug Interactions Drugs Interaction Ezetimibe Humans hypercholesterolaemia Male Middle Aged pharmacodynamics pharmacokinetics simvastatin Simvastatin - administration & dosage Simvastatin - pharmacokinetics Simvastatin - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!